The FLAURA2 study was led by Dr. Pasi A. Jänne from the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute in Boston, Mass.
Osimertinib, a potent third-generation EGFR-TKI with central nervous system activity, has garnered attention for its targeted inhibition of both sensitizing and resistance EGFR mutations. According to Dr. Jänne, The FLAURA2 trial builds on the favorable results observed in the phase III FLAURA trial, where osimertinib displayed superiority over comparator EGFR-TKIs.
The study enrolled 557 patients and randomized them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy. The combination arm involved a regimen of osimertinib alongside pemetrexed and either cisplatin or carboplatin. Results from the study demonstrated a remarkable improvement in progression-free survival with the osimertinib plus chemotherapy approach, showcasing a statistically significant reduction in disease progression risk compared to osimertinib monotherapy." Related StoriesThe data showed a compelling hazard ratio of 0.62 for progression-free survival, signifying an 8.8-month enhancement in median progression-free survival.
"These findings mark a significant advancement in the management of advanced EGFR-mutated NSCLC," Dr. Jänne reported. "The FLAURA2 study supports osimertinib combined with platinum-pemetrexed chemotherapy as a new and promising first-line treatment option, poised to make a profound impact on patient outcomes in this challenging disease setting."
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Taiwan National Lung Cancer Early Detection Program offers hope for saving lives through early diagnosisThe Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
Source: NewsMedical - 🏆 19. / 71 Read more »
Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancerThe immunotherapy drug, durvalumab, has been the standard of care for patients with stage III non-small cell lung cancer(NSCLC) to improve survival, when prescribed after chemotherapy and radiation therapy.
Source: NewsMedical - 🏆 19. / 71 Read more »
Stigmatization of smoking-related diseases is a barrier to care, and the problem may be on the riseThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Study aims to identify interventions to combat stigma associated with lung cancer and smoking-related respiratory diseasesThe stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »
Exhaled breath analysis shows promise in detecting malignant pleural mesotheliomaIdentifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Source: medical_xpress - 🏆 101. / 51 Read more »
Six-year follow-up data on survival, benefits for patients with metastatic NSCLC and nivolumab + ipilimumab treatmentResearch findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
Source: medical_xpress - 🏆 101. / 51 Read more »